Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Key Inclusion Criteria * Patients ≥ 18 years of age. * Baseline ECOG Performance Status ≤ 2, and patient is a candidate for intensive chemotherapy. * Newly diagnosed Ph+ ALL. * Written informed consent prior to any screening procedures. Permitted exceptions are that the diagnostic marrow exam/peripheral blood/nodal biopsy tests confirming Ph+ B-Cell ALL, as well as pre-induction cardiac workup (EKG/TTE/MUGA), may be performed prior to the patient providing written informed consent if these tests are within 14 days of enrollment. * Patient able to give informed consent. * B-cell Acute Lymphoblastic Leukemia with BCR-ABL1, i.e., Philadelphia chromosome-positive (Ph+) ALL. * B-Cell lineage determined by standard flow cytometry/IHC * Ph+ by cytogenetics (karyotype/FISH) and/or molecular (BCR-ABL1 transcripts) * Determined in CLIA-certified laboratory * Previously untreated, except for below allowances in a recent diagnosis and up until 48 hours after starting trial therapy: * Corticosteroids * Hydroxyurea * Leukapheresis Key Exclusion Criteria * Any of the following subtypes of ALL: * Ph-negative B-Cell ALL. * T-Cell ALL. * Relapsed Ph+ ALL. * Lymphoid blast crisis of chronic myeloid leukemia (CML). * Mature B-Cell (Burkitt's) ALL. * Clinical signs of CNS disease. * Active ALL in CNS or testes. * Estimated Glomerular Filtration Rate (eGFR) by MDRD formula and calculated creatinine clearance (CrCl), based on a 24-hour urine collection, \< 30 mL/min-unle…